Quyen N. Do
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Quyen N. Do has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Brandon Faubert
Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
41 shared publications - James Brugarolas
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
40 shared publications - Vanina Toffessi Tcheuyap
The University of Texas Southwestern Medical Center 11 Kidney Cancer Program, Simmons Comprehensive Cancer Center Dallas, Texas
39 shared publications - Payal Kapur
Kidney Cancer Program, Simmons Comprehensive Cancer Center
38 shared publications - Akhilesh Mishra
Department of Life Science, National Institute of Technology Rourkela
37 shared publications - Alana Christie
O’Donnell-SPH- Biostatistics Shared Resource, The University of Texas Southwestern Medical Center, Dallas, USA
37 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors and lungs from NSCLC patents.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors and lungs from NSCLC patents.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Overall and recurrence-free survival summary.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Overall and recurrence-free survival summary.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Transcriptomic data for NSCLC and adjacent lung tissue fragments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Transcriptomic data for NSCLC and adjacent lung tissue fragments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Patient Isotopologue Data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Patient Isotopologue Data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figures 5 and 6): Treatment with IACS-010759 reduces distant metastasis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figures 5 and 6): Treatment with IACS-010759 reduces distant metastasis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Clinical and pathological data from patients recruited to this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Clinical and pathological data from patients recruited to this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Epithelial and myeloid cell contributions to gene expression and 13C labeling features.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Epithelial and myeloid cell contributions to gene expression and 13C labeling features.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients